tbuckley/cabot-search huggingface dataset:
The Accelerated Medical Program and the Liberal Arts at Boston University
Authors: E. H. Blaustein
Journal: JAMA (1976)

Since September 1961, fifteen classes have matriculated in Boston University's Six-Year College of Liberal Arts-Medical Education Combined Degree Program. The applicant pool is approximately three to four times larger now than in the earlier years, with classes averaging 50 students. Academic qualifications (high-school class rank and Scholastic Aptitude Test and College Board Achievement Test results) of the entering classes have been at a consistently high level. Fifty percent or more of the graduates receive the BA degree with honors; 10% or more receive the MD degree with honors. The degree of flexibility in the liberal arts component of the program has increased and currently exceeds that of the traditional four-year premedical curriculum. These data, together with additional information concerning postgraduate professional activities, indicate that the combined accelerated program has been successful. (<i>JAMA</i>235:2618-2620, 1976)
Book Review Hereditary and Environmental Factors in the Causation of Manic-Depressive Psychoses and Dementia Precox . By Horatio M. Pollock, Benjamin Malzberg and Raymond G. Fuller. 8°, cloth, 473 pp., with 87 tables. Utica: State Hospitals Press, 1939. $2.50.
Journal: New England Journal of Medicine (1940)
Fake.
Authors: T J Hamblin
Journal: BMJ (1981)

The Latest Decalogue In the year that Popeye became once again a major movie star it is salutary to recall that his claims for spinach are spurious.Popeye's superhuman strength for deeds of derring-do comes from consuming a can of the stuff.The discovery that spinach was as valuable a source of iron as red meat was made in the 1890s, and it proved a useful propaganda weapon for the meatless days of the second world war.A statue of Popeye in Crystal City, Texas, commemorates the fact that single-handedly he raised the consumption of spinach by 33 7,.America was "strong to finish 'cos they ate their spinach" and duly defeated the Hun.Unfortunately, the propaganda was fraudulent; German chemists reinvestigating the iron content of spinach had shown in the 1930s that the original workers had put the decimal point in the wrong place and made a tenfold overestimate of its value.Spinach is no better for you than cabbage, Brussels sprouts, or broccoli.For a source of iron Popeye would have been better off chewing the cans (fig 1).Frauds, hoaxes, fakes, and widely popularised mistakes run through the warp and woof of the history of science and medicine.FIG 1-Popeye .. would have done better to eat the cans. National prideSometimes they become a matter of national pride.In 1903 Rene Blondlot, a distinguished French physicist at the University of Nancy, discovered N-rays, a new type of radiation.The rays were originally detected in the emissions of an electrical discharge tube but later were found to issue from a type of home gas light known as a Welsbach mantle and also from heated pieces of silver or iron, from the Nernst glower, and, more surprisingly, from the human body.They could be bent by an aluminium prism and were immediately put to use by Augustin Charpentier, the professor of medical physics at Nancy, to out-
Iron and B12 parameters in anemic cancer patients on chemotherapy presenting for epoetin alpha (EPO) therapy
Authors: D. H. Henry, N. V. Dahl
Journal: Journal of Clinical Oncology (2004)

8091 Background: A significant proportion of cancer patients receiving chemotherapy will present with or develop anemia. The cause of this anemia is often the inflammatory cytokine-mediated anemia of chronic disease associated with cancer and/or chemotherapy. We are currently performing a trial in anemic cancer patients on chemotherapy being treated with EPO to see if no iron, oral iron, or iv iron improves the Hb response. While this trial is still ongoing, we report here the initial anemia screening parameters for all patients considered for study. Methods: After giving informed consent, patients starting a cycle of chemotherapy were screened. Samples were sent to a central laboratory for screening if a recent Hb was <11g/dL, the pt was eligible for EPO therapy, and had not been treated with EPO during the preceding 30 days. Results: Of 261 patients screened (174 female), overall 44 pts (17%) had ferritin <100ng/mL, and 154 pts (59%) had transferrin (TSAT) < 20%. Among pts with ferritin <100ng/ml, 77% also had TSAT < 20%. While 216 pts (83%) had ferritin >100ng/mL, 120 of these (46% of all pts) also had TSAT <20%. Seventy pts (27%) had content of reticulocyte hemoglobin (CHR) < 32 g/dL. No pts had red blood cell folate < 93ng/mL. Of 5 pts with low B12, only one had elevated MCV. Conclusions: Our results indicate a surprising prevalence of B12 and/or Iron deficiency in anemic cancer patients presenting for EPO therapy. Possible iron deficiency was indicated by either TSAT <20 % (which may coexist with an elevated ferritin), ferritin of < 100ng/ml and/or CHR < 32 g/dL. A small but significant proportion of anemic cancer pts presenting for EPO therapy may have B12 or iron deficiency. A basic work up to rule out treatable causes of anemia such as B12 or iron deficiency should be performed. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Watson Laboratories Watson Pharma
Journal of Nutrition, Philadelphia
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
European Perspectives
Journal: Circulation (2012)

FESC, FAHA, FIACS, helped shape the direction of clinical cardiological therapy through his involvement in the development of new catheters and carried out groundbreaking research in a wide range of areas, including endothelial dysfunction and heart rate in heart failure.More recently, he has focussed on ethics and law in medicine.He set up the Centre for Ethics and Law at the University of Freiburg and chaired it from 2000 to 2007.He continues to organise lectures and clinical studies.In
Consultant Representation
Authors: P. R. J. Vickers
Journal: BMJ (1975)

the leadership was proved to be wrong.When we, the General Medical Services Commnittee negotiators, met her she was very reasonable and gave us assurances.However, we would have been pilloried, and rightly so, if we had accepted them without warning her that the collection of resignations was likely.Under stress politicians unite but our pro- fession fragments.Dr.
Pancreatic panniculitis.
Authors: R Brown, R Buckley, M Kelley
Journal: Journal of Clinical Oncology (1997)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1997.15.11.3418 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 9363875 Pancreatic panniculitis. R BrownxR BrownSearch for articles by this author , R BuckleyxR BuckleySearch for articles by this author , M KelleyxM KelleySearch for articles by this author Show More National Naval Medical Center and National Cancer Institute, Bethesda, MD, USA. https://doi.org/10.1200/JCO.1997.15.11.3418 PDF "Pancreatic panniculitis.." Journal of Clinical Oncology, 15(11), pp. 3418–3419© 1997 by American Society of Clinical Oncology
Effects of PBBs on Cattle. III. Target Organ Modification as Shown by Renal Function and Liver Biochemistry
Authors: F. L. Schanbacher, L. B. Willett, P. D. Moorhead, H. D. Mercer
Journal: Environmental Health Perspectives (1978)

Efforts were made to more clearly delineate target organs and mechanisms of toxicity for PBBs in cattle. Methods were developed to obtain sequential liver biopsies on bovine heifers which yield 0.5 to 1.0 g of tissue. PBB was fed at a dose of 250 mg/head/day to Holstein heifers for 202 days. This dose produced no clinical signs of toxicity in any of the heifers, yet this produced tissue PBB concentration of greater than 100 times the FDA tolerance in body fat of 0.3 ppm. Liver biopsies (0.5–1.0 g each) were taken at days 0, 90, and 180. The liver tissue was homogenized and microsomes were prepared. Dithionite difference spectra were determined on the carbon monoxide treated microsome suspension and the cytochrome P-450 content determined. Also, the 100,000g supernatant was saved for ornithine decarboxylase analysis as a measure of hepatocyte proliferative activity. Results of the cytochrome P-450 analysis showed a significant (p < 0.05) two-fold elevation (per gram of wet liver) by day 90 and remained significantly (p < 0.05) elevated on day 180. The cytochrome P-450 values of control animals not receiving PBBs showed no such increase with time. The biopsy procedure appeared not to adversely affect the liver cytochrome P-450 concentration in the control heifers. These results show that PBBs at a dose of 250 mg/day induced the drug metabolism system of the liver, of which the cytochrome P-450 is a part, indicating that the liver is a potential target organ for PBBs. However, this has not been shown to cause clear signs of hepatotoxicity in the cow as determined from histopathology or serum enzyme analyses. The observed elevation of gross liver weights of the PBB-treated animals might be an expected consequence of the cytochrome P-450 induction. In contrast to rodents, the kidney has been identified by histopathology as a target organ for PBB toxicity in cattle. However, renal function studies with 131I-sodium-iodohippurate and 125I-sodium iodothalamate in PBB treated cows indicated that PBB toxicity to the kidney did not affect glomerular filtration rate or effective renal plasma flow even though nephrotoxic effects were produced. From these studies, both liver (as expected) and kidney (unexpected) were affected by PBBs. For liver this did not result in hepatotoxicity while for kidney nephrotoxicity was produced but could not be mechanistically explained.
FDA Proposes Special Labeling and Packaging to Prevent Childhood Iron Poisoning
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Table of Contents
Authors: Niki Katsiki, Manfredi Rizzo, Dimitri Mikhailidis, Christos Mantzoros, Ioannis Drosos, Anna Tavridou, George Kolios, Yongin Cho, Eunyeong Choe, Yong-Ho Lee, Ji Seo, Younjeong Choi, Yujung Yun, Hye Wang, Woo Ahn, Bong Cha, Hyun Lee, Eun Kang, Chigusa Higuchi, Atsuko Nakatsuka, Jun Eguchi, Sanae Teshigawara, Motoko Kanzaki, Akihiro Katayama, Satoshi Yamaguchi, Naoto Takahashi, Kazutoshi Murakami, Daisuke Ogawa, Sakiko Sasaki, Hirofumi Makino, Jun Wada, Tianpeng Zheng, Attit Baskota, Yun Gao, Tao Chen, Haoming Tian, Fan Yang, Paul Lee, Vita Birzniece, A Umpleby, Anne Poljak, Ken Ho, Jane Ferguson, Rhia Shah, Rachana Shah, Nehal Mehta, Michael Rickels, Muredach Reilly, Anna Yliniemi, Mona-Marika Nurkkala, Sanni Kopman, Teemu Korpimaki, Heikki Kouru, Markku Ryynanen, Jaana Marttala, Seyed Hoseini, Ali Kalantari, Mohsen Afarideh, Sina Noshad, Aram Behdadnia, Manouchehr Nakhjavani, Alireza Esteghamati, Charles Glueck, Jessica Woo, Philip Khoury, John Morrison, Stephen Daniels, Ping Wang, Wen Guo, Jinxiang Fu, Xiaoli Chen, Beibei Gao, Zhenzhen Fu, Hongqi Fan, Qin Cui, Xiaohui Zhu, Yang Zhao, Tao Yang, Daping Fan, Erdim Sertoglu, Metin Uyanik, Huseyin Kayadibi, Serkan Tapan, Satoshi Imamura, Tomoaki Morioka, Yuko Yamazaki, Ryutaro Numaguchi, Hiromi Urata, Koka Motoyama, Katsuhito Mori, Shinya Fukumoto, Tetsuo Shoji, Masanori Emoto, Masaaki Inaba
Journal: Metabolism (2015)
Leprosy in New York.
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Eyebrows, plus or minus
Authors: F. A. Kingery
Journal: JAMA (1966)

Loss of eyebrow hair (madarosis) is one of those signs which delights the elegant practitioner of the art of physical diagnosis, for at a glance he can recognize a number of otherwise unrelated diseases. Hypertrichosis of the eyebrows is also a sign which demands explanation when not on the basis of heredity. On this page are a collection of illustrative examples in which changes in the normal pattern of eyebrow growth give a major clue to the underlying problem.
COMPULSORY NOTIFICATION OF TUBERCULOSIS.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Transactions of the Thirty-Eighth Annual Meeting of the Illinois State Medical Society
Journal: JAMA (1889)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Concurrent chemoradiotherapy with weekly platinum for patients with unresectable/locally advanced SCCHN and comorbidities
Authors: S. A. Limaye, S. Nissel-Horowitz, A. Caramalis, A. Thomas, B. Mehrotra
Journal: Journal of Clinical Oncology (2008)

17033 Background: Concomitant chemoradiotherapy (CRT) with cisplatin, given every three weeks, is a standard treatment option in the management of unresectable/ locally advanced squamous cell carcinoma of head and neck (SCCHN). Many patients are unable to tolerate the toxicity of standard dose cisplatin. The purpose of the present study was to evaluate the efficacy and feasibility of concurrent weekly dose platinum with RT in patients who have a poor performance status (PS) and multiple comorbidities. Methods: We retrospectively identified patients treated with weekly dosing of platinum and concomitant RT for locally advanced SCCHN. Carboplatin AUC 2 (n = 11) or Cisplatinum at 35 mg/m2 (n = 20) or both used alternately (n = 2) were given weekly, concurrently with RT. Median duration of treatment was 6 weeks. Treatment response was evaluated by clinical exam, PET and CT scans. Results: Thirty three patient charts were identified between 2003–2007. 28 patients had upfront treatment with CRT for their disease and 5 had recurrent disease. Primary sites of disease were: oral cavity (n = 6), oropharynx (n = 20), hypopharynx (n = 4) and occult primary with neck disease (n = 3). Stages: Stage III (n = 4), Stage IV A (n = 24) and Stage IV B (n = 5). 28 patients had CRT only and 5 had surgery followed by CRT. 23 patients (73%) had complete remission (CR), 3 (9%) had partial remission and 6 (18%) had progressive disease at the first follow-up imaging. Median duration of follow up was 14+ mo (range 5-45 mo) for all patients. 1 yr overall survival rate was 86% (n = 24/28) for upfront treatment and 60% (n = 3/5) for recurrent disease. Updated disease free survival at the median follow up will be available for the meeting. Conclusions: Concomitant weekly dose platinum and concomitant RT for unresectable/locally advanced SCCHN results in a high CR and survival rates in patients with poor PS and comorbidities. Although, the follow up of our series is short at this time, these results are comparable to those achieved with standard dose Cisplatinum 100 mg/m2 given every three weeks with RT. However, the weekly regimen is better tolerated in such patients. Prospective trials should be designed based on performance status scales to further validate the feasibility of this regimen. No significant financial relationships to disclose.
Comparative study of ceftriaxone and spectinomycin for treatment of pharyngeal and anorectal gonorrhea
Authors: F. N. Judson
Journal: JAMA (1985)

Of the currently recommended regimens for treatment of uncomplicated gonorrhea, only aqueous penicillin G procaine is effective against infections at all sites. However, procaine penicillin is not effective against penicillinase-producing<i>Neisseria gonorrhoeae</i>and suffers from poor patient acceptability owing to the 10-mL volume of injection and allergic and toxic procaine reactions. Ceftriaxone is a new extended-spectrum cephalosporin with a long serum half-life and is many times more active than penicillin G against both β-lactamase—positive or —negative strains of<i>N gonorrhoeae</i>. Ceftriaxone was compared as a single, 125-mg, 0.5-mL injection with a single 2-g injection of spectinomycin in difficult to treat pharyngeal gonorrhea in men and women and anorectal gonorrhea of men. Ceftriaxone cured 30/32 (94%) pharyngeal and 52/52 anorectal infections, compared with 6/14 (43%) and 9/9, respectively, for spectinomycin. Both regimens were well tolerated. Ceftriaxone may prove to be a drug of choice for uncomplicated gonorrhea, particularly where homosexual men are treated and/or penicillinase-producing<i>N gonorrhoeae</i>is prevalent. (<i>JAMA</i>1985;253:1417-1419)
Primary Hodgkin's disease of the CNS in an immunocompetent patient: A case study and review of the literature
Authors: Jim Biagi, Robert G. MacKenzie, Megan S. Lim, Michelle Sapp, Neil Berinstein
Journal: Neuro-Oncology (2000)

Primary Hodgkin's disease limited to the CNS is exceedingly rare.Little is known regarding etiologic risk factors, optimal management, and prognosis.A case of Hodgkin's disease con ned to the CNS, with cerebrospinal uid negative for cytology, is described in an immunocompetent patient previously treated for hyperthyroidism with 131 I.The patient underwent craniotomy, with resection of two lesions in close proximity within the parenchyma of the temporoparietal lobe.Histopathology revealed classic nodular sclerosing Hodgkin's disease, without evidence of Epstein-Barr viral infection.Treatment included radiation to the whole brain with a boost to the tumor bed.The patient made a full neurologic recovery and remains free of disease recurrence 21 months after treatment.A literature review has identi ed only 9 additional cases.Seven of 8 evaluable patients remain alive and free of recurrence with a median follow-up of 13 months.The risk factors for this presentation remain unde ned.Although followup is short, radiotherapy alone appears to provide excellent disease-free survival.Chemotherapy may be reserved for patients with positive cerebrospinal uid, extracranial disease, or subsequent relapse.